Allogene Therapeutics vs Creative Medical Technology
ALLO and CELZ side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ALLO and CELZ compare
Allogene Therapeutics is the larger company, worth 75 times as much as Creative Medical Technology ($311M against $4.2M).
Creative Medical Technology scores higher on the StockData Score (7 against 3 for Allogene Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ALLO | CELZ |
|---|---|---|
| Size and price | ||
| Market cap | $311M | $4.2M |
| Share price | $0.900 | $0.630 |
| Change, 1 year | −23.7% | −80.8% |
| Change, 5 years | −95.2% | −98.2% |
| Beta (5Y) | 1.62 | 1.56 |
| Employees | 152 | – |
| StockData Score | ||
| Total score | 3 | 7 (better) |
| Valuation score | 1 | 1 |
| Growth score | 0 | 1 (better) |
| Performance score | 1 (better) | 0 |
| Health score | 1 | 5 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | – | 1384× |
| P/B | 0.8× | 0.6× (better) |
| FCF yield | −35.0% | – |
| Growth | ||
| Revenue growth (TTM) | – | −50.0% |
| Revenue growth, 5Y average | – | −48.4% |
| Profitability | ||
| Gross margin | – | 66.9% |
| Operating margin | – | −256435% |
| Net margin | – | −249160% |
| Return on equity | −49.3% (better) | −119% |
| Return on invested capital | −718% (better) | −3737% |
| Financial health | ||
| Debt / equity | – | 0.00 |
| Interest coverage | −142.5× | – |
| Current ratio | 7.79 | 23.66 (better) |
| Altman Z-score | −4.92 (better) | −8.55 |
| Piotroski F-score | 3 | 4 (better) |
| Dividends and buybacks | ||
| Dividend yield | 0.00% | – |
| Years of dividend growth | 0 | – |
| Buyback yield | – | −190% |
| Shareholder yield | 0.00% (better) | −190% |
| Ownership | ||
| Held by institutions | 90.5% | 5.7% |
| Held by insiders | 15.0% | 15.9% |
| Insider net buying, 12 months | −$668K | – |
| Short interest, % of float | 17.5% | 1.2% |
Go deeper
- ALLO stock overview
- ALLO income statement
- ALLO valuation and score
- CELZ stock overview
- CELZ income statement
- CELZ valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.